Breaking News Instant updates and real-time market news.

UROV

Urovant Sciences

$11.03

-3.03 (-21.55%)

06:27
03/20/19
03/20
06:27
03/20/19
06:27

JPMorgan boosts Urovant target to $24, calls selloff yesterday unfounded

JPMorgan analyst Eric Joseph raised his price target for Urovant Sciences to $24 from $20 saying he views the Empowur data, "showing clear and early separation from placebo across all primary and secondary endpoints, as a key de-risking event for the program." The data support "best-in-class commercial" for vibegron in overactive bladder, Joseph tells investors in a research note. The analyst views yesterday's stock pullback as unfounded and sees an attractive entry point at current share levels. He keeps an Overweight rating on Urovant Sciences.

UROV Urovant Sciences
$11.03

-3.03 (-21.55%)

10/22/18
COWN
10/22/18
INITIATION
Target $25
COWN
Outperform
Urovant Sciences initiated with an Outperform at Cowen
Cowen analyst Ritu Baral initiated Urovant Sciences with an Outperform rating to reflect the potential of vibegron, which she expects to be successful in its Phase 3 trial based on a positive Phase 2 precedent. She estimates $1.6B in peak potential sales based on a 22% market shares. Baral has a $25 price target on Urovant Sciences shares.
03/11/19
HCWC
03/11/19
INITIATION
Target $28
HCWC
Buy
Urovant Sciences initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Raghuram Selvaraju started Urovant Sciences with a Buy rating and $28 price target. The analyst believes vibegron, a novel beta-3 adrenergic receptor agonist aimed at treatment of overactive bladder and other indications, represents an "attractively-positioned investment opportunity."
03/15/19
RHCO
03/15/19
INITIATION
Target $24
RHCO
Buy
Urovant Sciences initiated with a Buy at SunTrust
SunTrust analyst Edward Nash initiated Urovant with a Buy rating and a price target of $24, saying the stock offers a "compelling risk-reward" and the possibility of a strong near-term data readout from its pivotal Phase III EMPOWUR trial for vibegron later this month. The analyst cites his conviction for a positive readout in patients with overactive bladder based on the approval of vibegron in Japan and also points to Astellas' Myrbetriq, which is a drug from the same class as that of Urovant, being commercially available in the U.S. since 2012. Nash sees vibegron total revenue potential for the company of as much as $2.8B by 2032.
03/15/19
03/15/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Simmons First National (SFNC) initiated with a Buy at DA Davidson. 2. Amgen (AMGN) and Gilead (GILD) initiated with an Outperform at BMO Capital. 3. Rocket Pharmaceuticals (RCKT) initiated with a Buy at BofA/Merrill. 4. Urovant Sciences (UROV) initiated with a Buy at SunTrust. 5. Spectrum (SPPI) assumed with a Buy at Jefferies. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.

TODAY'S FREE FLY STORIES

CNP

CenterPoint Energy

$26.68

-1.42 (-5.05%)

05:21
11/15/19
11/15
05:21
11/15/19
05:21
Downgrade
CenterPoint Energy rating change  »

CenterPoint Energy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GPRK

GeoPark

$18.92

-0.02 (-0.11%)

05:20
11/15/19
11/15
05:20
11/15/19
05:20
Hot Stocks
GeoPark announces all-cash acquisition of Amerisur Resources »

GeoPark announces the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MITK

Mitek Systems

$7.70

-0.34 (-4.23%)

05:18
11/15/19
11/15
05:18
11/15/19
05:18
Downgrade
Mitek Systems rating change  »

Mitek Systems downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ATLKY

Atlas Copco

$0.00

(0.00%)

05:18
11/15/19
11/15
05:18
11/15/19
05:18
Downgrade
Atlas Copco rating change  »

Atlas Copco downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SALRF

Salmar

$0.00

(0.00%)

05:16
11/15/19
11/15
05:16
11/15/19
05:16
Upgrade
Salmar rating change  »

Salmar upgraded to Hold…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CNP

CenterPoint Energy

$26.68

-1.42 (-5.05%)

05:14
11/15/19
11/15
05:14
11/15/19
05:14
Downgrade
CenterPoint Energy rating change  »

CenterPoint Energy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DDAIF

Daimler AG

$0.00

(0.00%)

05:13
11/15/19
11/15
05:13
11/15/19
05:13
Downgrade
Daimler AG rating change  »

Daimler AG downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SWAV

ShockWave Medical

$36.47

1.38 (3.93%)

05:11
11/15/19
11/15
05:11
11/15/19
05:11
Syndicate
ShockWave Medical 2.482M share Secondary priced at $36.25 »

The deal size was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

05:10
11/15/19
11/15
05:10
11/15/19
05:10
General news
FX Action: The yen is trading softer »

FX Action: The yen is…

BGNE

BeiGene

$195.90

-1.25 (-0.63%)

05:09
11/15/19
11/15
05:09
11/15/19
05:09
Recommendations
BeiGene analyst commentary  »

BeiGene price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 27

    Feb

NXTC

NextCure

$38.60

0.85 (2.25%)

05:09
11/15/19
11/15
05:09
11/15/19
05:09
Syndicate
NextCure 4.08M share Secondary priced at $36.75 »

The deal size was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

AAPL

Apple

$262.66

-1.86 (-0.70%)

05:05
11/15/19
11/15
05:05
11/15/19
05:05
Recommendations
Apple price target raised to $290 from $270 at Piper Jaffray »

Piper Jaffray analyst…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

QCOM

Qualcomm

$90.48

0.03 (0.03%)

, AAPL

Apple

$262.66

-1.86 (-0.70%)

04:59
11/15/19
11/15
04:59
11/15/19
04:59
Upgrade
Qualcomm upgraded to Buy from Neutral at Mizuho »

Mizuho analyst Vijay…

QCOM

Qualcomm

$90.48

0.03 (0.03%)

AAPL

Apple

$262.66

-1.86 (-0.70%)

SSNLF

Samsung

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

NUE

Nucor

$54.49

-0.2 (-0.37%)

04:55
11/15/19
11/15
04:55
11/15/19
04:55
Conference/Events
Nucor management to meet with KeyBanc »

Management participates…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

INS

Intelligent Systems

$42.26

-0.34 (-0.80%)

04:55
11/15/19
11/15
04:55
11/15/19
04:55
Conference/Events
Intelligent Systems management to meet with Sidoti »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

EXPI

eXp World Holdings

$9.97

-0.08 (-0.80%)

04:55
11/15/19
11/15
04:55
11/15/19
04:55
Conference/Events
eXp World Holdings management to meet with DA Davidson »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

GSHD

Goosehead Insurance

$44.75

0.02 (0.04%)

04:55
11/15/19
11/15
04:55
11/15/19
04:55
Conference/Events
Goosehead Insurance management to meet with William Blair »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

  • 03

    Dec

04:55
11/15/19
11/15
04:55
11/15/19
04:55
General news
Industrial Production Capacity Utilization Rate to be reported at 09:15 »

October Industrial…

04:55
11/15/19
11/15
04:55
11/15/19
04:55
General news
Business Inventories to be reported at 10:00 »

September Business…

04:55
11/15/19
11/15
04:55
11/15/19
04:55
Conference/Events
CLSA to hold a forum »

22nd CLSA India Forum…

04:55
11/15/19
11/15
04:55
11/15/19
04:55
General news
Breaking General news story  »

Week of 11/15…

TRGP

Targa Resources

$38.03

-0.28 (-0.73%)

04:55
11/15/19
11/15
04:55
11/15/19
04:55
Conference/Events
Targa Resources management to meet with RBC Capital »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

UBX

Unity Biotechnology

$6.30

-0.26 (-3.96%)

04:55
11/15/19
11/15
04:55
11/15/19
04:55
Conference/Events
Unity Biotechnology management to meet with Mizuho »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

  • 13

    Dec

CTSO

CytoSorbents

$4.24

-0.2 (-4.50%)

04:55
11/15/19
11/15
04:55
11/15/19
04:55
Conference/Events
CytoSorbents management to meet with B. Riley FBR »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

FTNT

Fortinet

$100.07

0.38 (0.38%)

04:55
11/15/19
11/15
04:55
11/15/19
04:55
Conference/Events
Fortinet management to meet with MKM Partners »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

  • 18

    Nov

  • 19

    Nov

  • 05

    Dec

  • 06

    Dec

  • 09

    Dec

  • 12

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.